Related Experiment Video

Updated: Aug 18, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Transforming growth factor-beta and Smad signalling in kidney diseases

Wansheng Wang1, Vijay Koka, Hui Y Lan

  • 1Department of Medicine-Nephrology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.

Nephrology (Carlton, Vic.)
|February 12, 2005
PubMed

Insights

Transforming growth factor-beta (TGF-beta) signaling via Smad2/3 drives kidney fibrosis. Overexpressing Smad7 blocks this and inflammation, offering therapeutic potential for kidney diseases.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor-beta (TGF-beta) is implicated in renal disease progression.
  • Smad2 and Smad3 are key downstream mediators of TGF-beta.
  • The precise role of Smad2 in TGF-beta-induced renal fibrosis requires further elucidation.

Purpose of the Study:

  • To investigate the role of Smad signaling in renal fibrosis induced by various factors.
  • To determine the mechanisms by which Smad7 inhibits renal fibrosis and inflammation.
  • To explore the therapeutic potential of targeting Smad signaling in kidney diseases.

Main Methods:

  • Overexpression of inhibitory Smad7 to block Smad2/3 activation.
  • Assessment of collagen matrix production and renal fibrosis in animal models.
  • Analysis of TGF-beta's anti-inflammatory and immune-regulatory effects.

Main Results:

  • Smad3 is critical for TGF-beta's pro-fibrotic effects; Smad2's role is less clear.
  • Other factors like angiotensin II and AGE activate Smads independently of TGF-beta.
  • Smad7 overexpression prevented collagen production and attenuated fibrosis across multiple kidney disease models.
  • TGF-beta demonstrated anti-inflammatory properties by upregulating Smad7, inhibiting NF-kappaB activation.

Conclusions:

  • Smad signaling acts as a final common pathway for renal fibrosis.
  • TGF-beta signaling through Smad2/3 mediates renal fibrosis.
  • Smad7 induction inhibits both renal fibrosis and inflammation, suggesting therapeutic potential.

More Related Videos

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay11:38

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...